Logo

RevoluGen: Annalisa Jenkins

Feb 23, 2022

RevoluGen has appointed Annalisa Jenkins as the company’s chair of the board of directors. Prior to joining RevoluGen, Jenkins served as the executive VP, head of global research and development, and a member of the pharmaceutical executive committee for Merck Serono. Before that, she had a 14-year career at Bristol-Myers Squibb as the senior VP and head of global medical affairs. Jenkins also currently serves as a board member of several healthcare companies including Affimed, AoBiome, Avrobio, Cocoon Biotech, Compass Pathways, Oncimmune, Ori Biotech, Perspectum, and Phaim Pharma along with various governmental, academic, and non-profit organizations positions in the U.K. and U.S. Jenkins holds a degree in medicine from St. Bartholomew’s Hospital, University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.

 

Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.